HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,046,335 | -12.7% | 105,925 | -17.5% | 0.00% | 0.0% |
| Q2 2023 | $4,633,083 | -29.5% | 128,447 | -25.4% | 0.00% | -40.0% |
| Q1 2023 | $6,572,729 | +37.1% | 172,106 | +104.3% | 0.01% | +25.0% |
| Q4 2022 | $4,793,200 | -43.8% | 84,239 | -60.9% | 0.00% | -33.3% |
| Q3 2022 | $8,528,000 | +83.0% | 215,709 | +103.7% | 0.01% | +100.0% |
| Q2 2022 | $4,659,000 | +188.7% | 105,884 | +161.8% | 0.00% | +200.0% |
| Q1 2022 | $1,614,000 | -76.1% | 40,452 | -75.9% | 0.00% | -75.0% |
| Q4 2021 | $6,747,000 | +59.9% | 167,798 | +61.8% | 0.00% | +100.0% |
| Q3 2021 | $4,220,000 | -23.8% | 103,725 | -15.0% | 0.00% | -33.3% |
| Q2 2021 | $5,538,000 | -55.6% | 121,964 | -59.3% | 0.00% | -62.5% |
| Q1 2021 | $12,479,000 | +489.5% | 299,311 | +503.9% | 0.01% | +700.0% |
| Q4 2020 | $2,117,000 | +59.4% | 49,562 | -1.9% | 0.00% | – |
| Q3 2020 | $1,328,000 | -72.1% | 50,536 | -71.5% | 0.00% | -100.0% |
| Q2 2020 | $4,753,000 | +60.4% | 177,288 | +7.6% | 0.00% | 0.0% |
| Q1 2020 | $2,964,000 | +10.4% | 164,752 | +8.8% | 0.00% | 0.0% |
| Q4 2019 | $2,684,000 | +6.1% | 151,412 | -7.1% | 0.00% | 0.0% |
| Q3 2019 | $2,529,000 | +20.0% | 163,034 | +32.9% | 0.00% | +50.0% |
| Q2 2019 | $2,107,000 | +31.2% | 122,685 | +23.0% | 0.00% | +100.0% |
| Q1 2019 | $1,606,000 | -64.2% | 99,755 | -67.5% | 0.00% | -80.0% |
| Q4 2018 | $4,485,000 | +168.6% | 306,544 | +233.5% | 0.01% | +400.0% |
| Q3 2018 | $1,670,000 | +65.0% | 91,924 | +53.3% | 0.00% | – |
| Q2 2018 | $1,012,000 | -72.9% | 59,965 | -68.5% | 0.00% | -100.0% |
| Q1 2018 | $3,732,000 | -31.1% | 190,550 | -28.7% | 0.00% | -60.0% |
| Q4 2017 | $5,413,000 | +91.4% | 267,185 | +64.1% | 0.01% | +150.0% |
| Q3 2017 | $2,828,000 | +74.7% | 162,842 | +28.9% | 0.00% | +100.0% |
| Q2 2017 | $1,619,000 | +15.4% | 126,290 | +16.7% | 0.00% | 0.0% |
| Q1 2017 | $1,403,000 | -63.2% | 108,220 | -71.9% | 0.00% | -66.7% |
| Q4 2016 | $3,810,000 | +271.3% | 385,668 | +354.2% | 0.00% | – |
| Q3 2016 | $1,026,000 | +58.6% | 84,908 | +13.2% | 0.00% | – |
| Q2 2016 | $647,000 | -53.5% | 74,992 | -49.0% | 0.00% | -100.0% |
| Q1 2016 | $1,391,000 | +7.1% | 146,955 | +96.0% | 0.00% | 0.0% |
| Q4 2015 | $1,299,000 | -32.3% | 74,960 | -47.5% | 0.00% | 0.0% |
| Q3 2015 | $1,918,000 | +0.7% | 142,844 | +69.4% | 0.00% | -50.0% |
| Q2 2015 | $1,905,000 | +340.0% | 84,342 | +178.1% | 0.00% | – |
| Q1 2015 | $433,000 | -9.4% | 30,328 | -38.9% | 0.00% | – |
| Q4 2014 | $478,000 | +31.0% | 49,599 | +23.7% | 0.00% | – |
| Q3 2014 | $365,000 | +73.8% | 40,094 | +87.9% | 0.00% | – |
| Q2 2014 | $210,000 | -72.2% | 21,334 | -64.1% | 0.00% | -100.0% |
| Q1 2014 | $755,000 | +30.6% | 59,436 | +54.1% | 0.00% | 0.0% |
| Q4 2013 | $578,000 | +117.3% | 38,562 | +59.9% | 0.00% | – |
| Q3 2013 | $266,000 | +3225.0% | 24,119 | +2607.0% | 0.00% | – |
| Q2 2013 | $8,000 | – | 891 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |